Growth Metrics

Merck (MRK) Short term Debt (2016 - 2026)

Merck has reported Short term Debt over the past 18 years, most recently at $2.4 billion for Q1 2026.

  • Quarterly Short term Debt rose 79.71% to $2.4 billion in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $2.4 billion through Mar 2026, up 79.71% year-over-year, with the annual reading at $2.6 billion for FY2025, 2.27% down from the prior year.
  • Short term Debt was $2.4 billion for Q1 2026 at Merck, down from $2.6 billion in the prior quarter.
  • Over five years, Short term Debt peaked at $3.1 billion in Q3 2024 and troughed at $887.0 million in Q3 2023.
  • The 5-year median for Short term Debt is $2.4 billion (2026), against an average of $2.2 billion.
  • Year-over-year, Short term Debt tumbled 83.34% in 2022 and then skyrocketed 255.02% in 2024.
  • A 5-year view of Short term Debt shows it stood at $1.9 billion in 2022, then decreased by 29.5% to $1.4 billion in 2023, then surged by 93.08% to $2.6 billion in 2024, then fell by 2.27% to $2.6 billion in 2025, then dropped by 5.6% to $2.4 billion in 2026.
  • Per Business Quant, the three most recent readings for MRK's Short term Debt are $2.4 billion (Q1 2026), $2.6 billion (Q4 2025), and $1.4 billion (Q3 2025).